If you've left a fertility consult feeling like the answer didn't quite fit your body, you're not alone, and increasingly, the medical literature agrees with you. The most current research on diagnostic delay in fertility-affecting conditions explicitly treats patient self-report as data, not noise. Your instinct that something is being missed is, more often than the workup paperwork suggests, the same instinct the field is starting to listen to.
Here are seven questions worth bringing to your next appointment.
"Could my fertility doctor be missing endometriosis even though my ultrasound was normal?"
Short answer: yes, easily.
The new ACOG Clinical Practice Guideline 11 on endometriosis diagnosis, published in February 2026, explicitly acknowledges that imaging can be negative while disease is active, and that a presumptive diagnosis based on symptoms and clinical exam is now appropriate. Superficial endometriotic lesions, which can affect implantation and egg quality, frequently don't show on transvaginal ultrasound. Deep-infiltrating endometriosis can show, but only if the sonographer is specifically looking at recognized landmarks like the rectovaginal septum and uterosacral ligaments, using one of the standardized protocols.
What to ask: "Was my ultrasound performed using IDEA or MUSA criteria? Given my symptom history, would you consider an empiric treatment trial under the new ACOG guidance?"
"What's actually the difference between endometriosis and adenomyosis, and why does it matter for fertility?"
Plain language: endometriosis grows endometrial-like tissue outside the uterus, on ovaries, bowel, pelvic walls, sometimes well beyond the pelvis. Adenomyosis grows endometrial tissue into the muscular wall of the uterus. They're related conditions and often coexist (some specialists put the overlap at 20 to 40 percent), but they affect fertility differently.
Adenomyosis is associated with lower clinical pregnancy and live birth rates and roughly double the miscarriage rate in IVF, per a 2017 meta-analysis in Fertility and Sterility30484-3/fulltext). Endometriosis affects egg quality, tubal anatomy, and the implantation environment in different ways. If you've been evaluated for one and not the other, it's worth asking why.
"Should I push for an MRI if my transvaginal ultrasound was clear?"
Worth discussing, especially if you have any of these:
A history suggestive of deep-infiltrating endometriosis (severe cyclical bowel or bladder symptoms, painful intercourse with a specific positional pattern, pain that radiates to your lower back)
Persistent suspicion of adenomyosis (heavy, prolonged bleeding, an enlarged or "bulky" uterus on exam)
An "unexplained infertility" label and you want a more complete picture before deciding on next steps
MRI's sensitivity for adenomyosis is roughly 77 percent versus transvaginal ultrasound's 75 percent, per the 2023 meta-analysis in International Journal of Gynecology and Obstetrics. Not a dramatic difference, but MRI is more consistent across operators and better at characterizing depth. For endometriosis, MRI is particularly useful for mapping deep disease before any surgical decision.
"When is laparoscopy actually necessary anymore?"
Less often than it used to be. It's no longer the diagnostic gold standard, per ESHRE 2022, ACOG 2026, and the updated NICE NG73 in 2024. But it still has clear roles:
When imaging is negative and empiric medical treatment hasn't worked
When deep-infiltrating endometriosis is suspected and imaging hasn't fully mapped it
When surgical treatment itself is on the table (excision can be both diagnostic and therapeutic, particularly with a surgeon trained in excision technique)
In some cases of severe disease where staging affects treatment planning
The bigger shift is that you no longer need surgery to get a diagnosis and start treatment.
"I was told I had PCOS years ago. Is that still the right diagnosis?"
Worth re-checking. The diagnostic criteria have tightened twice since 2003.
The 2023 International Evidence-Based PCOS Guideline, led by Dr. Helena Teede at Monash University and endorsed by 39 organizations including ASRM, allows AMH testing to substitute for ovarian ultrasound in confirming polycystic morphology, and tightens what counts as androgen excess and ovulatory dysfunction. When researchers re-applied the newer criteria to women previously diagnosed under Rotterdam, only about three-quarters still met the stricter 2023 definition.
Phenotype matters for fertility treatment. Women with PCOS-A (the classic hyperandrogenic, anovulatory, polycystic-ovaries triad) often respond differently to ovulation induction than women whose original diagnosis really reflected a different metabolic picture. A re-evaluation could change your treatment plan.
"My cycles are irregular and I'm under 40. Could this be POI?"
It could. The updated ESHRE guideline on premature ovarian insufficiency, endorsed by ASRM in 2025, says POI can now be diagnosed with four months of irregular cycles plus FSH above 25 IU/L in someone under 40. That's a looser threshold than the older "three months of amenorrhea plus repeated FSH above 30" standard, which means more women, earlier, now meet criteria.
The guideline also explicitly notes that AMH alone is not diagnostic for POI. If you've been given a verbal interpretation of a low AMH without a fuller workup, that's worth flagging. POI's implications run well beyond fertility, including bone and cardiovascular health, which makes early, complete diagnosis matter more than the conversation often suggests.
"How do I find a doctor who'll actually listen?"
Look for a few things.
Excision-trained surgeons, often listed through the Endometriosis Foundation of America, which Padma Lakshmi co-founded with Dr. Tamer Seckin. Reproductive endocrinologists who specifically discuss endometriosis, adenomyosis, and POI as part of their workup, not just bloodwork and a couple of standard scans. A consult that includes a careful symptom history, not only lab values. A clinician who can name the relevant guidelines without checking.
The shift in these guidelines, and the slow change in how some fertility workups are run, has a quieter implication that doesn't always make it into the patient pamphlet: trusting your own read of your body is no longer outside the medical mainstream. The most current literature on diagnostic delay treats patient self-report as data. Your instinct that something is being missed is, more often than not, the same instinct the field is finally starting to follow.
Resources
· ESHRE, Endometriosis Guideline (2022) and POI Guideline (2024)
· Monash University, International PCOS Guideline (2023)
· Endometriosis Foundation of America, endofound.org
· BackTable OBGYN, Navigating Adenomyosis (podcast)
